One World Business
Shiva Ayyadurai’s story highlights how often society can assume knowledge is owned and monopolized by the powerful few. Knowledge must be fostered at every age, in every corner of the globe. Intelligence is not solely the property of the rich, the powerful, or the well-connected.
With the support of teachers and mentors, Shiva developed the program we know today as “e-mail” and the young age of just 14. His creation, though, was not without controversy as his innovation was heatedly debated by academics, huge companies and the media.
21:35 | 2014
Dr. V.A. Shiva Ayyadurai, the inventor of email and polymath, holds four degrees from MIT, is a world-renowned systems scientist, inventor and entrepreneur. His love of medicine and complex systems began in India when he became intrigued with medicine at the age of five as he observed his grandmother, a farmer and healer in the small village of Muhavur in South India, apply Siddha, India’s oldest system of traditional medicine, to heal and support local villagers. These early experiences inspired him to pursue the study of modern systems science, information technology and eastern and traditional systems of medicine to develop an integrative framework linking eastern and western systems of medicine.
In 1978, as a precocious 14-year-old, after completing a special program in computer science at the Courant Institute of Mathematical Science at NYU, Ayyadurai was recruited by the University of Medicine and Dentistry of New Jersey (UMDNJ) as a Research Fellow, where he developed the first electronic emulation of the entire interoffice mail system (Inbox, Outbox, Folders, Address Book, Memo, etc.), which he named “EMAIL,” to invent the world’s first email system, resulting in him being awarded the first United States Copyright for Email, Computer Program for Electronic Mail System, at a time when Copyright was the only protection for software inventions.
Today, he is the Chairman & CEO of CytoSolve, Inc. CytoSolve provides a revolutionary platform for modeling complex diseases as well as for discovering multi-combination therapeutics. His recent efforts at CytoSolve have led to an FDA allowance and exemption for a multi-combination drug for pancreatic cancer, development of innovative nutraceutical products, as well as numerous industry and academic partnerships.
Visit his website https://vashiva.com/